trending Market Intelligence /marketintelligence/en/news-insights/trending/7JmBU6e7TrLp6IiH8DWBBA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Merck's HIV drug gets US FDA approval

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Merck's HIV drug gets US FDA approval

The U.S. FDA approved Merck & Co. Inc.'s Isentress HD for treating HIV-1 infection in adult and pediatric patients in combination with other anti-retroviral agents.

Isentress HD is a new 1,200-milligram, once-daily dose of the company’s integrase inhibitor, Isentress, for patients weighing at least 40 kilograms who have not received prior treatment or whose virus has been suppressed on an initial regimen of Isentress 400 milligrams given twice daily.

The approval of Isentress HD was supported by the results of a pivotal phase 3 study that showed that 89% of treatment-naive patients who received the drug achieved viral suppression of HIV-1 RNA, or viral load, of less than 40 copies per milliliter, compared to 88% of patients receiving Isentress 400 milligrams twice a day, each in combination therapy with emtricitabine + tenofovir disoproxil fumarate.

Merck expects the drug to be available in pharmacies in about four weeks.